Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol

Ophthalmic Surgery Lasers and Imaging

Volumn 41, Issue 3, 2010, Pages 316-322

  Panagiotoglou, Theonitsa D ^a   Ganotakis, Emmanuel S ^a   Kymionis, George D ^c   Moschandreas, Joanna A ^b   Fanti, Garufalia N ^a   Charisis, Spyridon K ^a   Malliaraki, Niki E ^a   Tsilimbaris, Miltiadis K ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; OPHTHALMOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETINA EXUDATE; RETINA HEMORRHAGE; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ACUITY;

ADMINISTRATION, ORAL; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77952604460     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20100430-04     Document Type: Article

References (27)

1. Singer DE, Nathan DM, Fogel HA, et al. Screening for diabetic retinopathy. Ann Intern Med. 1992;116:660-671.
2. Farmer JA. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Atheroscler Rep. 2007;9:162-168. (Pubitemid 47376987)
3. Reaven GM. Abnormal lipoprotein metabolism in non-insulin diabetes mellitus. Am J Med. 1987;83:31-40.
4. Klein BEK, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XII: relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology. 1991;98:1261-1265.
5. Chew EY, Klein ML, Ferris FL III. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy: ETDRS report 22. Arch Ophthalmol. 1996;114:1079-1084.
6. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26:2653-2664.
7. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48-58.
8. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
9. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology. 1991;98:1594-1602.
10. Watanabe J, Wohltman HJ, Klein RL, Colwell JA, Lopes-Virella MF. Enhancement of platelet aggregation by low-density lipoprotein from IDDM patients. Diabetes. 1988;37:1652-1657. (Pubitemid 19004949)
11. Nordoy A, Svensson B, Weibe D, Hoak JC. Lipoproteins and the inhibitory effect of human endothelial cells on platelet function. Circ Res. 1978;43:527-534. (Pubitemid 9022295)
12. Lyons TJ, Li W, Wojciechowski B, Wells-Knecht MC, Wells-Knecht KJ, Jenkins AJ. Aminoguanidine and the effects of modified LDL on cultured retinal capillary cells. Invest Ophthalmol Vis Sci. 2000;41:1176-1180. (Pubitemid 30187557)
13. Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986;83:8370-8374.
14. Furberg CD. Natural statins and stroke risk. Circulation. 1999;99:185-188.
15. Harrold BP, Marmion VJ, Gough KR. A double blind controlled trial of clofibrate in the treatment of DR. Diabetes. 1969;18:285-291.
16. Hammes HP, Weiss A, Fuhrea D, et al. Acceleration of experimental diabetic retinopathy in the rat by omega-3 fatty acid. Diabetologia. 1996;39:251-255. (Pubitemid 26064820)
17. Robinson JG. Simvastatin: present and future perspectives. Expert Opin Pharmacother. 2007;8:2159-2227
18. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1-11. (Pubitemid 34170743)
19. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol. 2004;137:675-682. (Pubitemid 38446682)
20. Gordon B, Chang S, Kavanagh M, et al. The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991;112:385-391.
21. Friedewald WJ, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
23. American Diabetes Association. Clinical Practice Recommendations 2007. Diabetes Care. 2007;30(suppl 1):S16-S17.
24. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
25. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
26. Fleisher LN, Tall AR, Witte LD, et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem. 1982;257:6653-6655. (Pubitemid 12022261)
27. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylgyratyl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719. (Pubitemid 34219772)